BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23108199)

  • 1. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome.
    Huang G; Coviello A
    Curr Opin Endocrinol Diabetes Obes; 2012 Dec; 19(6):512-9. PubMed ID: 23108199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovary syndrome and the metabolic syndrome.
    Weerakiet S
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S189-93. PubMed ID: 21213522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin resistance syndrome and polycystic ovary syndrome: implications for diagnosis and treatment.
    Tan S; Hahn S; Janssen OE
    Panminerva Med; 2005 Dec; 47(4):211-7. PubMed ID: 16489320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular disease risk factors in polycystic ovary syndrome.
    Dokras A
    Semin Reprod Med; 2008 Jan; 26(1):39-44. PubMed ID: 18181081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease risk in women with PCOS.
    Dokras A
    Steroids; 2013 Aug; 78(8):773-6. PubMed ID: 23624351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
    Gateva AT; Kamenov ZA
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome.
    Moran L; Teede H
    Hum Reprod Update; 2009; 15(4):477-88. PubMed ID: 19279045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population.
    Sirmans SM; Parish RC; Blake S; Wang X
    J Investig Med; 2014 Aug; 62(6):868-74. PubMed ID: 24844662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
    Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
    Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
    Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
    J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
    Tomlinson J; Millward A; Stenhouse E; Pinkney J
    Diabet Med; 2010 May; 27(5):498-515. PubMed ID: 20536945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
    Verit FF
    Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening women with polycystic ovary syndrome for metabolic syndrome.
    Dokras A; Bochner M; Hollinrake E; Markham S; Vanvoorhis B; Jagasia DH
    Obstet Gynecol; 2005 Jul; 106(1):131-7. PubMed ID: 15994628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications.
    Sirmans SM; Weidman-Evans E; Everton V; Thompson D
    Ann Pharmacother; 2012 Mar; 46(3):403-18. PubMed ID: 22388330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance and polycystic ovary syndrome.
    Galluzzo A; Amato MC; Giordano C
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome in polycystic ovary syndrome.
    Essah PA; Wickham EP; Nestler JE
    Clin Obstet Gynecol; 2007 Mar; 50(1):205-25. PubMed ID: 17304037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of appropriate patients for cardiometabolic risk management.
    Peters AL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S9-16. PubMed ID: 17934394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.